Copyright
©The Author(s) 2023.
World J Clin Cases. Oct 6, 2023; 11(28): 6688-6697
Published online Oct 6, 2023. doi: 10.12998/wjcc.v11.i28.6688
Published online Oct 6, 2023. doi: 10.12998/wjcc.v11.i28.6688
Table 1 Baseline clinical profiles of enrolled individuals
Disease | n | Sex (male/female) | Age (yr) |
Systemic lupus erythematosus | 138 | 8/130 | 11-77 |
Sicca syndrome | 48 | 2/46 | 18-83 |
Rheumatoid arthritis | 50 | 14/36 | 20-85 |
Scleroderma | 12 | 3/9 | 38-69 |
Dermatomyositis | 22 | 7/15 | 9-78 |
Healthy controls | 130 | 31/99 | 14-79 |
Table 2 Detection rate of antinuclear antibody spectrum, n (%)
Items | Chemiluminescence method | Immunochemistry | χ2 | P value | ||||||
SLE | SS | Other | Total | SLE | SS | Other | Total | |||
Anti-double-stranded DNA (dsDNA) antibody | 69 (50.00) | 5 (10.42) | 3 (3.57) | 77 (28.52) | 61 (44.20) | 4 (8.33) | 3 (3.57) | 68 (25.19) | 0.764 | 0.382 |
Anti-histone (Histone) antibody | 32 (23.19) | 4 (8.33) | 5 (5.95) | 41 (15.19) | 35 (25.36) | 4 (8.33) | 7 (8.33) | 46 (17.04) | 0.343 | 0.558 |
Anti-nucleosome (Nuc) antibody | 40 (28.99) | 1 (2.08) | 4 (4.76) | 45 (16.67) | 36 (26.09) | 1 (2.08) | 3 (3.57) | 40 (14.81) | 0.349 | 0.555 |
Anti-Smith (Sm) antibody | 18 (13.04) | 1 (2.08) | 2 (2.38) | 21 (7.78) | 17 (12.32) | 0 (0.00) | 1 (1.19) | 18 (6.67) | 0.249 | 0.618 |
Anti-ribosomal P protein (Rib-P) antibody | 38 (27.54) | 2 (4.17) | 0 (0.00) | 40 (14.81) | 49 (35.51) | 2 (4.17) | 0 (0.00) | 51 (18.89) | 1.599 | 0.206 |
Anti-sicca syndrome A (Ro60) antibody | 82 (59.42) | 40 (83.33) | 14 (16.67) | 136 (50.37) | 85 (61.59) | 36 (75.00) | 13 (15.48) | 134 (49.62) | 0.030 | 0.863 |
Anti-sicca syndrome A (Ro52) antibody | 77 (55.80) | 37 (77.08) | 19 (23.46) | 133 (49.26) | 79 (57.25) | 36 (75.00) | 21 (25.00) | 136 (50.37) | 0.067 | 0.796 |
Anti- sicca syndrome (SSB) antibody | 19 (13.77) | 18 (37.50) | 12 (14.29) | 49 (18.15) | 20 (14.49) | 19 (39.58) | 11 (13.10) | 50 (18.52) | 0.012 | 0.911 |
Anti-centromere protein B (Cenp-B) antibody | 11 (7.97) | 4 (8.33) | 2 (2.38) | 17 (6.30) | 8 (5.80) | 3 (6.25) | 2 (2.38) | 13 (4.81) | 0.565 | 0.452 |
Anti-DNA topoisomerase 1 (Scl-70) antibody | 5 (3.62) | 0 (0.00) | 6 (7.14) | 11 (4.07) | 4 (2.90) | 0 (0.00) | 6 (7.14) | 10 (3.70) | 0.050 | 0.824 |
Anti-histidyl tRNA synthetase (Jo-1) antibody | 0 (0.00) | 0 (0.00) | 1 (1.19) | 1 (0.37) | 1 (0.72) | 0 (0.00) | 1 (4.62) | 2 (0.74) | 0.335 | 0.563 |
Anti-mitochondrial M2 (AMA-M2) antibody | 2 (1.45) | 1 (2.08) | 3 (3.57) | 6 (2.22) | 2 (1.45) | 0 (0.00) | 3 (3.57) | 5 (1.85) | 0.093 | 0.761 |
Table 3 Agreement rate of antinuclear antibody spectrum (%)
Items | Positive agreement rate | Negative agreement rate | Total agreement rate | Kappa | P value |
Anti-double-stranded DNA (dsDNA) antibody | 89.71 | 92.08 | 91.48 | 0.783 | < 0.05 |
Anti-histone (Histone) antibody | 82.61 | 98.66 | 95.93 | 0.849 | < 0.05 |
Anti-nucleosome (Nuc) antibody | 90.00 | 96.09 | 95.19 | 0.819 | < 0.05 |
Anti-Smith (Sm) antibody | 83.33 | 97.62 | 96.67 | 0.751 | < 0.05 |
Anti-ribosomal P protein (Rib-P) antibody | 64.71 | 96.80 | 90.74 | 0.671 | < 0.05 |
Anti-sicca syndrome A (Ro60) antibody | 93.28 | 91.91 | 92.59 | 0.852 | < 0.05 |
Anti-sicca syndrome A (Ro52) antibody | 91.18 | 92.59 | 92.22 | 0.844 | < 0.05 |
Anti- sicca syndrome (SSB) antibody | 88.00 | 97.73 | 95.93 | 0.864 | < 0.05 |
Anti-centromere protein B (Cenp-B) antibody | 92.31 | 98.05 | 97.78 | 0.788 | < 0.05 |
Anti-DNA topoisomerase 1 (Scl-70) antibody | 80.00 | 98.85 | 98.15 | 0.752 | < 0.05 |
Anti-histidyl tRNA synthetase (Jo-1) antibody | 50.00 | 100.00 | 99.63 | 0.665 | < 0.05 |
Anti-mitochondrial M2 (AMA-M2) antibody | 80.00 | 99.25 | 98.89 | 0.722 | < 0.05 |
Table 4 Diagnostic performance of antibodies detected by chemiluminescence assay and line immunoassay for systemic lupus erythematosus
Antibodies | Chemiluminescence method | Line immunoassay | ||
AUC | 95%CI | AUC | 95%CI | |
Anti-double-stranded DNA (dsDNA) antibody | 0.935 | 0.907-0.962 | 0.905 | 0.871-0.940 |
Anti-histone (Histone) antibody | 0.508 | 0.436-0.580 | 0.513 | 0.441-0.585 |
Anti-nucleosome (Nuc) antibody | 0.837 | 0.788-0.886 | 0.829 | 0.780-0.879 |
Anti-Smith (Sm) antibody | 0.941 | 0.914-0.968 | 0.907 | 0.872-0.943 |
Anti-ribosomal P protein (Rib-P) antibody | 0.776 | 0.721-0.831 | 0.791 | 0.738-0.844 |
Anti-sicca syndrome A (Ro60) antibody | 0.953 | 0.931-0.975 | 0.945 | 0.921-0.969 |
Anti-sicca syndrome A (Ro52) antibody | 0.946 | 0.920-0.972 | 0.929 | 0.900-0.958 |
Anti- sicca syndrome (SSB) antibody | 0.650 | 0.584-0.716 | 0.661 | 0.596-0.727 |
Anti-centromere protein B (Cenp-B) antibody | 0.811 | 0.761-0.861 | 0.787 | 0.733-0.841 |
Anti-DNA topoisomerase 1 (Scl-70) antibody | 0.783 | 0.727-0.838 | 0.740 | 0.681-0.800 |
Anti-histidyl tRNA synthetase (Jo-1) antibody | 0.821 | 0.769-0.874 | 0.781 | 0.722-0.841 |
Anti-mitochondrial M2 (AMA-M2) antibody | 0.895 | 0.844-0.947 | 0.920 | 0.883-0.957 |
- Citation: Xiang HY, Xiang XY, Ten TB, Ding X, Liu YW, Luo CH. Clinical value of chemiluminescence method for detection of antinuclear antibody profiles. World J Clin Cases 2023; 11(28): 6688-6697
- URL: https://www.wjgnet.com/2307-8960/full/v11/i28/6688.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i28.6688